Jefferies Financial Group Inc. Buys Shares of 24,600 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Jefferies Financial Group Inc. acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 24,600 shares of the specialty pharmaceutical company's stock, valued at approximately $890,000.

Several other large investors have also recently added to or reduced their stakes in SUPN. Gotham Asset Management LLC grew its position in Supernus Pharmaceuticals by 3.8% in the 4th quarter. Gotham Asset Management LLC now owns 39,212 shares of the specialty pharmaceutical company's stock worth $1,418,000 after purchasing an additional 1,419 shares during the last quarter. Graham Capital Management L.P. bought a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $250,000. Deutsche Bank AG increased its position in Supernus Pharmaceuticals by 226.2% in the 4th quarter. Deutsche Bank AG now owns 105,583 shares of the specialty pharmaceutical company's stock valued at $3,818,000 after acquiring an additional 73,213 shares during the period. D. E. Shaw & Co. Inc. boosted its position in Supernus Pharmaceuticals by 33.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock worth $19,731,000 after acquiring an additional 136,870 shares during the period. Finally, Cubist Systematic Strategies LLC grew its stake in shares of Supernus Pharmaceuticals by 944.2% in the fourth quarter. Cubist Systematic Strategies LLC now owns 139,522 shares of the specialty pharmaceutical company's stock worth $5,045,000 after purchasing an additional 126,161 shares in the last quarter.

Supernus Pharmaceuticals Price Performance

Shares of SUPN traded down $0.38 during midday trading on Monday, reaching $33.05. The stock had a trading volume of 463,727 shares, compared to its average volume of 489,802. The firm's 50 day moving average price is $31.88 and its 200-day moving average price is $34.84. The company has a market capitalization of $1.85 billion, a P/E ratio of 30.89 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 8.80% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SUPN shares. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.